CJC-1295 UK legal status
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue. It is not a UK-licensed medicine. WADA prohibits GHRH analogues under S2. This page covers the UK regulatory position, the ‘CJC + ipamorelin’ stack, and the implications for sellers, clinics, and athletes.
Current UK regulatory framing
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Two variants circulate: CJC-1295 with DAC (extended half-life via Drug Affinity Complex conjugation) and CJC-1295 without DAC (a shorter-acting variant often called Mod GRF 1-29).
Neither variant has a UK marketing authorisation. The original pharmaceutical development of CJC-1295 with DAC was discontinued after a safety event in early-phase clinical trials. The compound has continued to circulate as a research peptide.
The evidence base
CJC-1295 mechanistic data is reasonable: it does increase mean GH and IGF-1 levels in published short-term studies. The translation from those changes to the marketed body-composition, recovery, and anti-ageing outcomes is much less well supported in humans. Long-term safety in non-deficient adults is not established.
The dose-response, frequency, and stacking patterns used in the consumer market come from research-peptide-forum convention rather than from licensed-medicine clinical trials.
Sport — WADA S2
GHRH analogues including CJC-1295 fall under S2 of the WADA Prohibited List (peptide hormones, growth factors, related substances and mimetics). Prohibited at all times, both in and out of competition. Strict liability applies.
The ‘CJC + ipamorelin’ stack
The most-marketed pairing combines CJC-1295 (baseline GH increase) with ipamorelin (a selective GH secretagogue, adds a pulse). It is framed as a “safer alternative to HGH”. The framing glosses over several issues:
- Both are unlicensed in the UK. The combination has no UK marketing authorisation.
- Both are S2 for athletes. A combination doesn’t mitigate the anti-doping risk; it multiplies it.
- Manipulating the GH axis with two compounds simultaneously is not pharmacologically gentler than a single compound. It is just two simultaneous interventions on the same axis.
- Long-term safety in non-deficient adults is unknown for either compound and not better-known for the combination.
See ipamorelin UK legal status and our Claim Interaction Explorer for the evidence-gap framing.
What this means in practice
For sellers
CJC-1295 sold with GH-stack instructions, IGF-1 promises, or body-recomposition claims is presented as a medicine. Unlicensed supply offences and advertising offences apply.
For clinics
A UK clinic offering CJC-1295 as “peptide therapy” for anti-ageing or body composition is supplying an unlicensed compound with implied GH-axis effects and no licensed medicine to fall back on.
For athletes
Direct WADA strict-liability risk. Testing for GHRH analogues and for resulting IGF-1 / GH disturbance is established.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“CJC-1295 + ipamorelin — safer than HGH”
Both unlicensed in the UK. Both S2 in sport. ‘Safer than’ comparisons are not supported by clinical data.
“Pharma-grade CJC-1295 DAC — UK delivery”
‘Pharma-grade’ is unverifiable in the grey market. CJC-1295's pharmaceutical development was discontinued — there is no genuine pharma-grade reference product.
“Anti-ageing peptide therapy — real GH boost”
Implied medicinal claim for an unlicensed substance. Clinics promoting this engage MHRA and CQC scrutiny.
“Stack with ipamorelin for serious results”
Marketing language. The stack is not characterised in human RCTs and creates concurrent S2 risk for athletes.
Sources & further reading
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- WADA Prohibited List (S2 — Peptide Hormones and Growth Factors) — wada-ama.org
- Global DRO — globaldro.com
Frequently asked questions
- Is CJC-1295 legal in the UK?
- CJC-1295 is not a licensed UK medicine. Supplying it as a medicine or with medicinal claims is unlawful under the Human Medicines Regulations 2012.
- Is CJC-1295 prohibited in sport?
- Yes. GHRH analogues are prohibited under S2 of the WADA Prohibited List (peptide hormones, growth factors, related substances and mimetics) at all times. Strict liability applies.
- What's the difference between ‘CJC-1295 with DAC’ and ‘without DAC’?
- ‘CJC-1295 DAC’ has a Drug Affinity Complex that extends half-life from minutes to days, giving sustained GH release. ‘CJC-1295 without DAC’ (Mod GRF 1-29) has a shorter half-life and pulsatile profile. Both are unlicensed in the UK; both are S2.
- Why is CJC-1295 commonly ‘stacked’ with ipamorelin?
- CJC-1295 increases baseline GH release; ipamorelin (a GH secretagogue) adds a pulse. The combination is heavily marketed in the research-peptide space. There is no UK marketing authorisation for the combination and no human RCT evidence for the marketed outcomes.
- Can a UK clinic prescribe CJC-1295?
- There is no UK licensed CJC-1295 to prescribe. A clinic offering ‘peptide therapy’ with CJC-1295 is offering an unlicensed substance for a human-health purpose — and the implied GH-axis manipulation has well-known clinical risks.